Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests’ Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium
Veracyte, Inc. (VCYT)
Last veracyte, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.veracyte.com/investor-relations
Company Research
Source: Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that 17 Decipher-focused abstracts will be presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU). The findings demonstrate the market leadership of its Decipher tests in better informing treatment decisions for patients with prostate and bladder cancers, compared to standard approaches, and in helping to drive innovation that will inform the future of urologic cancer care. The conference will take place February 13-15 in San Francisco.“The scale and scope of data to be presented at the ASCO GU meeting underscore the impact our whole-transcriptome-based Decipher tests are having in treatin
Read more
Impact Snapshot
Event Time:
VCYT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VCYT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VCYT alerts
High impacting Veracyte, Inc. news events
Weekly update
A roundup of the hottest topics
VCYT
News
- Veracyte (VCYT) Surged on Reporting Strong Earnings [Yahoo! Finance]Yahoo! Finance
- Veracyte Full Year 2024 Earnings: EPS Misses Expectations [Yahoo! Finance]Yahoo! Finance
- Top 3 Medical Instruments Industry Stocks to Ride the GenAI Boom [Yahoo! Finance]Yahoo! Finance
- Veracyte, Inc. (NASDAQ: VCYT) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Veracyte, Inc. (NASDAQ: VCYT) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $45.00 price target on the stock.MarketBeat
VCYT
Earnings
- 2/24/25 - Beat
VCYT
Sec Filings
- 3/10/25 - Form 4
- 3/10/25 - Form 4
- 3/10/25 - Form 4
- VCYT's page on the SEC website